Related Experiment Video

Updated: Apr 12, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K

New treatment options in castration-resistant prostate cancer

Andrew J Armstrong1

  • 1Presented by Andrew J. Armstrong, MD, ScM, Associate Professor of Medicine, Co-Director of Clinical Research Program, Duke Cancer Institute, Durham, North Carolina.

Journal of the National Comprehensive Cancer Network : JNCCN
|May 22, 2015
PubMed

Insights

The 2015 NCCN Guidelines for prostate cancer highlight new systemic therapies for metastatic castration-resistant and castration-sensitive prostate cancer. Key developments include novel agents, immunotherapy insights, and AR-V7 as a predictive biomarker.

Area of Science:

  • Oncology
  • Urology
  • Medical Guidelines

Background:

  • The 2015 NCCN Clinical Practice Guidelines for Prostate Cancer address significant updates in systemic therapy.
  • Focus areas include metastatic castration-resistant prostate cancer (mCRPC) and castration-sensitive prostate cancer (mCSPC).

Purpose of the Study:

  • To summarize key developments in prostate cancer systemic therapy presented at the NCCN 20th Annual Conference.
  • To highlight advancements in treatment strategies for advanced prostate cancer.

Main Methods:

  • Review of updates to the 2015 NCCN Guidelines for Prostate Cancer.
  • Discussion of recent clinical findings and emerging biomarkers by Dr. Andrew J. Armstrong.

Main Results:

  • Conflicting data exists regarding docetaxel repurposing in castration-sensitive disease.
  • Immunotherapy may offer survival benefits in specific mCRPC populations.
  • Updated data on androgen receptor (AR) and biosynthesis inhibitors are available.
  • Androgen-receptor splice variant 7 messenger RNA (AR-V7) is an emerging biomarker for treatment response.

Conclusions:

  • The 2015 NCCN Guidelines reflect progress in systemic treatments for advanced prostate cancer.
  • Emerging biomarkers like AR-V7 are crucial for personalizing treatment strategies.
  • Continued research is essential to optimize outcomes for patients with metastatic prostate cancer.

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

1.1K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.3K

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.7K